Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar
Current problems in cardiology
Cardiology Division; Fellows and Residents; USF-LVHN SELECT Program Students
Acute Coronary Syndrome (ACS) is a term that describes pathologies related to myocardial ischemia, and is comprised of unstable angina, non-ST elevation myocardial infarction, and ST elevation myocardial infarction. Urgent management of ACS is typically necessary to prevent future morbidity and mortality. Current medical recommendations of ACS management involve use of dual antiplatelet therapy, typically with aspirin and clopidogrel. However, newer therapies are being designed and researched to improve outcomes for patients with ACS. Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events. It has been Food and Drug Administration approved for reduction of thrombotic cardiovascular events in patients with a history of MI or peripheral arterial disease with concomitant use of clopidogrel and/or aspirin, based upon the findings of the TRA 2°P-TIMI 50 trial. However, Vorapaxar was also found to have a significantly increased risk of bleeding, which must be considered when administering this drug. Based upon further subgroup analysis of both the TRA 2°P-TIMI 50 trial and TRACER trial, Vorapaxar was found to be potentially beneficial in patients with peripheral artery disease, coronary artery bypass grafting, and ischemic stroke. There are current trials in progress that are further evaluating the use of Vorapaxar in those conditions, and future research and trials are necessary to fully determine the utility of this drug.
Gupta, R., Lin, M., Mehta, A., Aedma, S. K., Shah, R., Ranchal, P., Vyas, A., Singh, S., Kluck, B. W., Combs, W., & Patel, N. C. (2021). Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. LVHN Scholarly Works. Retrieved from https://scholarlyworks.lvhn.org/research-historical-works/22